Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?

Irmak Duygu Koyuncu, Darıcı Hakan, Karaöz Erdal

Table 6 The MSC treatment doses, route of administration, treatment/ application intervals and target lung condition’s name and grade (mild, moderate, severe or critical).

Trial ID Therapy Route Dose Application intervals Condition ChiCTR2000029569 Conventional treatment (CT) combined with UC-MSC conditioned medium Not mentioned Not mentioned Not Mentioned Severe or/to critical pneumonia diagnosis due to SARS-CoV infection ChiCTR2000030138 CT + UC-MSC CT + placebo IV injection Not mentioned Not Mentioned Severe Novel Coronavirus Pneumonia ChiCTR2000029990 MSCs or saline Not mentioned Not mentioned Not Mentioned Moderate to severe cases of new coronavirus pneumonia ChiCTR2000030300 (Cancelled) (UC-MSCs) Not mentioned Not mentioned Not Mentioned Patients with high risk ChiCTR2000031494 CT or CT plus UC-MSCs IV Not mentioned Not Mentioned Severe novel coronavirus pneumonia ChiCTR2000031430 CT + UC-MSCs IV 4*107 cells/application on days 0, 3, and 6 for a total of 3 times Novel Coronavirus Pneumonia (COVID-19) severity not mentioned NCT04252118 CT plus MSCs IV 1*107cells/application at Day 0, Day 3, Day 6). Pneumonia Patients Infected With COVID-19 severity not mentioned NCT04276987 CT plus MSCs-derived exosomes aerosol inhalation 1*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5 Severe or/to critical pneumonia diagnosis due to SARS-CoV infection NCT04313322 WJ-MSCs IV 1*106 cells/kg The three doses will be 3 days apart form each other. 3 weeks follow up COVID-19 (ever, respiratory destress, pneumonia, cough, sneezing, diarrhea) severity not mentioned NCT04313322 WJ-MSCs IV 1*10e6 cells/kg The three doses will be 3 days apart form each other. COVID-19 (ever, respiratory destress, pneumonia, cough, sneezing, diarrhea) severity not mentioned. NCT04315987 CT plus MSCs IV 2*107cells/application on days 1, 3 and 5 and if necessary on day 7 Severe COVID-19 pneumonia. NCT04331613 CAStem, immunity- and matrix-regulatory cells (IMRCs), differentiated from hESCs IV 3/5/10*106 cells/kg. Escalating doses. intervals not mentioned 3 cohorts with 3 patients/cohort with severe COVID-19 associated w/wo ARDS. NCT04339660 CT plus MSCs IV 1*106 cells/kg 1 time, or with an interval of 1 week Critically ill COVID-19 pneumonia NCT04336254 CT plus hDP-MSCs IV 3*107cells/bag * 3 bags injection of on day 1, day 4 and day 7 Severe pneumonia caused by COVID-19 NCT04288102 CT plus MSCs IV 4.0*107 at Day 0, Day 3, Day 6. COVID-19 Patients with Severe Convalescence NCT04302519 CT plus hDP-MSCs IV 1.0x106 cells /kg. on day 1, 3 and 7 of the trial. Novel Coronavirus Induced Severe Pneumonia NCT04269525 UC-MSCs IV 3.3*107/50ml bags*3bag, on day 1, day 3, day 5, and day 7. Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection